Correction: Mudie et al. In Vitro-In Silico Tools for Streamlined Development of Acalabrutinib Amorphous Solid Dispersion Tablets. Pharmaceutics 2021, 13, 1257

The authors wish to make the following corrections to this paper [1].

There was an error in the original article in the Abstract section, where it was stated that the absolute average fold error (AAFE) of the in silico predictions for AUC_0-inf for Calquence + famotidine was ≈3. A correction has been made to the abstract section: “In silico simulations of the HPMCAS-H ASD tablet and Calquence capsule provided good in vivo study prediction accuracy using a bottom–up approach (absolute average fold error of AUC_0-inf < 2)”.

There was an error in the original article in the Results section (Section 3.6, paragraph 1), where it was stated that AAFE of the in silico predictions for AUC_0-inf for the Calquence capsule + famotidine treatment was not <2. A correction has been made in the original article in the Results section (Section 3.6, paragraph 1): “The AAFE of the in silico predictions for AUC_0-inf, C_max, T_max, and C_p versus time for all formulation treatments were <2-fold (ideal value = 1) with the exception of C_p versus time for the Calquence capsule + famotidine treatment, indicating that the in silico prediction framework is sufficient for simulating acalabrutinib blood plasma concentrations within this in vivo study”.

In the original article, there were mistakes in Table 4 as published, where AAFE for AUC_0-inf for the Calquence capsule + pentagastrin was listed as 1.2 and AAFE for AUC_0-inf for Calquence capsule + famotidine was listed as 3.6. The corrected Table 4 appears below.

The authors apologize for any inconvenience caused and state that the scientific conclusions are unaffected. The original publication has also been updated.